Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 13/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 5/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22691655 | 1.00 | FGFR2 (0.36) | FGFR2FGFR3ACVRL1FGFR1FGFR4 | |
| SCHEMBL25557535 | 0.95 | ACVRL1 (0.33) | FGFR2FGFR3ACVRL1FGFR1FGFR4 | |
| SCHEMBL23337052 | 0.81 | ACVRL1 (0.48) | FGFR2FGFR3ACVRL1FGFR1FGFR4 | |
| SCHEMBL25217016 | 0.80 | FGFR2 (0.39) | FGFR2FGFR3FGFR1FGFR4 | |
| SCHEMBL29535127 | 0.80 | FGFR2 (0.39) | FGFR2FGFR3FGFR1FGFR4 | |
| SCHEMBL22695926 | 0.79 | ACVRL1 (0.37) | ACVRL1 | |
| SCHEMBL22691919 | 0.77 | FGFR2 (0.35) | FGFR2FGFR3FGFR1FGFR4 | |
| SCHEMBL22696352 | 0.77 | FGFR2 (0.49) | FGFR2FGFR3FGFR1FGFR4 | |
| SCHEMBL22691721 | 0.77 | FGFR2 (0.49) | FGFR2FGFR3FGFR1FGFR4 | |
| SCHEMBL22691719 | 0.77 | FGFR2 (0.49) | FGFR2FGFR3FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174535-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230174535-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-06-08 | — | — | US | disclosed |
| CN-114127051-A | Inhibitors of fibroblast growth factor receptor kinase | 金耐特生物制药公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2020236524-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. (US) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174535-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | FGFR2 2/4885FGFR3 3/4885ACVRL1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.